Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9NQ48
UPID:
LZTL1_HUMAN
Alternative names:
-
Alternative UPACC:
Q9NQ48; B3KSI9; B4E0K7; Q8TC61; Q9NQ56
Background:
Leucine zipper transcription factor-like protein 1 plays a pivotal role in regulating the ciliary localization of the BBSome complex, crucial for sonic hedgehog (SHH) pathway regulation and potentially impacting neurite outgrowth and tumor suppression. Its involvement in Bardet-Biedl syndrome 17, characterized by severe pigmentary retinopathy, obesity, and polydactyly, underscores its biological significance.
Therapeutic significance:
Given its critical role in Bardet-Biedl syndrome 17, targeting Leucine zipper transcription factor-like protein 1 offers a promising avenue for therapeutic intervention, potentially addressing the syndrome's multifaceted manifestations including obesity, polydactyly, and renal malformations.